Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalated furmonertinib plus bevacizumab, VP shunt, and intrathecal pemetrexed for EGFR-mutant NSCLC with leptomeningeal metastases
ChiCTR2600131551Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib, bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) and Carcinomatous Meningitis (CM), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Overall survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
furmonertinibbevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2600131551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131551.